The purpose of this study is to see if using the MedLog is helpful to patients. Since the
investigators do not yet know if this MedLog is helpful, some patients will receive it and
some will receive our standard of care. The investigators want to know whether providing
patients with this additional information is helpful and if having this additional
information about their treatment schedule has an effect on their quality of life.
- Diagnosis of lymphoma
- No prior treatment for lymphoma
- Scheduled to receive CHOP14 +/- Rituximab, CEOP 21, CHOPE or EPOCH +/- Rituximab
- Age 18 or older
- Able to speak and read English
- Documented major psychopathology or cognitive impairment likely in the judgment of
the research staff to interfere with the participation or completion of the protocol.